Eiropas Savienība - latviešu - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiski līdzekļi - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. papildinformāciju par cilvēka epidermas augšanas faktora 2 receptora (her2) statusu, lūdzu, skatiet 5. sadaļā. vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. sīkāku informāciju par her2 statusu, lūdzu, skatiet 5. sadaļā. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - vakcīnas - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4. 2 un 5. 1 in product information document). izmantojot šo vakcīnu, kas būtu saskaņā ar oficiālās rekomendācijas.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomīds - multiplā skleroze, recidivējoši-pārskaitot - imūnsupresanti - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomīds - multiplā skleroze, recidivējoši-pārskaitot - immunosuppressants, selektīvi immunosuppressants - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

norton healthcare ltd. - paclitaxel - sarcoma, kaposi; carcinoma, non-small-cell lung; ovarian neoplasms; breast neoplasms - antineoplastiski līdzekļi - paxene ir indicēts, lai ārstētu pacientus ar:• uzlabotas ar aids saistītu kapoši sarkoma (aids-ks), kas ir izdevies, pirms liposomal anthracycline terapija;• metastātisks vēzis krūts (mbc), kas nav izdevies, vai nav kandidātu standarta anthracycline-satur terapija;• uzlabotas vēzis olnīcu (aoc) vai ar atlikušo slimības (> 1 cm) pēc sākotnējās laparotomija, kopā ar cisplatin kā pirmās līnijas ārstēšanu;• metastātisks vēzis olnīcu (km) pēc neveiksmes ar platīnu saturošu kombinēto terapiju, bez taxanes kā otrās līnijas apstrāde;• nav maza šūnu plaušu vēzis (nsclc), kas nav kandidātu uz potenciāli dziednieciska operācijas un/vai staru terapiju, kopā ar cisplatin. ierobežoti dati par efektivitāti apstiprina šo indikāciju (skatīt 5. apakšpunktu).

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

pharmathen s.a. - irbesartan - hipertensija - agents, kas iedarbojas uz renīna-angiotenzīna sistēmu - sabervel ir indicēts pieaugušajiem esenciālas hipertensijas ārstēšanai. tas arī ir indicēts, lai ārstētu nieru slimības pieaugušiem pacientiem ar hipertensiju un 2. tipa cukura diabētu, kā daļa no antihipertensīvā zāles režīms.

Latvija - latviešu - Zāļu valsts aģentūra

medochemie ltd., cyprus - venlafaksīns - ilgstošās darbības kapsula, cietā - 75 mg

Latvija - latviešu - Zāļu valsts aģentūra

medochemie ltd., cyprus - venlafaksīns - ilgstošās darbības kapsula, cietā - 37,5 mg

Latvija - latviešu - Zāļu valsts aģentūra

medochemie ltd., cyprus - venlafaksīns - ilgstošās darbības kapsula, cietā - 150 mg

Latvija - latviešu - Zāļu valsts aģentūra

teva b.v., netherlands - tiotropijs - inhalācijas pulveris, cietā kapsula - 10 μg